Prolactin secretion in testicular cancer patients.
The role of prolactin (PRL) in testicular function and in its disorders is still obscure. To draw some preliminary conclusions on the relation between the PRL and testis cancer, we assessed the PRL response to thyrotropin-releasing hormone (THR) in 15 patients with testicular cancer (8 seminoma; 6 nonseminoma; 1 leydigioma), and in 11 healthy male subjects as controls. The results showed that 5/15 cancer patients gave no PRL response to TRH; 4 of them had a nonseminoma and the fifth a seminomatous testis carcinoma. Patients with nonseminoma had significantly lower mean peak values of PRL after TRH than controls or patients with seminoma. The biological significance of the altered PRL response to TRH in testicular carcinoma has still to be established.
Lissoni
P
P
Division of Radiation Oncology, Ospedale San Gerardo, Monza-Italy.
Crispino
S
S
Barni
S
S
Tancini
G
G
D000328:Adult; D004407:Dysgerminoma / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011863:Radioimmunoassay; D013736:Testicular Neoplasms / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D013997:Time Factors
D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin